Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CFO Mardi Dier will leave the company on November 15, 2022, for a new role at ACELYRIN, INC. Ted Huizenga and Aaron Olsen will manage finance activities during the search for Dier's successor. CEO Emil Kakkis praised Dier's contributions over her two-plus years at Ultragenyx, highlighting the company's fiscal responsibility heading into 2023. Ultragenyx focuses on developing novel therapies for rare genetic diseases, aiming to provide safe and effective treatments.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences. The events include the Stifel Healthcare Conference on November 15, 2022, at 1:50 PM EST in New York and the Jefferies London Healthcare Conference on November 17, 2022, at 10:25 AM GMT. Live and archived webcasts will be available on the company's website for 90 days. Ultragenyx is dedicated to developing novel therapies for serious rare diseases, focusing on unmet medical needs with its diverse portfolio of approved treatments.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported third-quarter 2022 total revenue of $90.7 million, including $64.5 million from Crysvita. The company reaffirms its 2022 revenue guidance for Crysvita between $250 million and $260 million, and Dojolvi between $55 million and $65 million. Operating expenses reached $315.8 million, leading to a net loss of $245.1 million or $3.50 per share. Key clinical milestones include completion of enrollment for several pivotal trials expected by year-end.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on November 2, 2022, at 5:00 PM ET to discuss Q3 2022 financial results and corporate updates. This call will provide insights into the company's performance and strategic direction as it focuses on developing therapies for rare genetic diseases. The live webcast will be accessible via the company's website, along with a replay available for a year. Ultragenyx aims to deliver effective therapies promptly, addressing significant unmet medical needs in the rare disease space.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options totaling 13,000 shares and 6,500 restricted stock units to a newly hired non-executive officer. Approved by the compensation committee, these awards are part of the Employment Inducement Plan under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $41.41 per share. The stock options and restricted stock units vest over four years, contingent on continuous employment.
On September 9, 2022, Ultragenyx Pharmaceutical (NASDAQ: RARE) and Mereo BioPharma (NASDAQ: MREO) announced the presentation of new data from Mereo's Phase 2b ASTEROID study and details of the Phase 2/3 Orbit study at the ASBMR Annual Meeting in Austin, Texas, running from September 9-12, 2022. Setrusumab, a monoclonal antibody for Osteogenesis Imperfecta (OI), will be discussed, highlighting its significance for the 60,000 OI patients in the US and Europe. Key presentations include results from the ASTEROID study and insights from the IMPACT Survey.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, Chief Medical Officer of Gene Therapy, will join a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on September 7, 2022, at 11:20 AM ET. This panel discussion highlights the company’s commitment to addressing serious rare and ultra-rare genetic diseases. Participants can access the live and archived webcast on Ultragenyx's website, available for 90 days post-event. Ultragenyx focuses on developing innovative therapies for high unmet medical needs in rare diseases.
On August 17, 2022, Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the granting of stock options and restricted stock units to two new non-executive officers. A total of 19,020 stock options and 12,910 restricted stock units were awarded under the Ultragenyx Employment Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $49.31, matching the closing price on the grant date. The vesting schedule includes a four-year period with certain conditions based on continued employment.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of non-qualified stock options for 27,500 shares and 14,500 restricted stock units to two newly hired non-executive officers. This award follows the Ultragenyx Employment Inducement Plan and was approved by the compensation committee on August 1, 2022. The stock options have a ten-year term with an exercise price of $50.63 per share. The restricted stock units vest over four years, promoting employee retention and aligning interests with shareholders.
Ultragenyx Pharmaceutical reported Q2 2022 total revenue of $89.3 million, with Crysvita revenue at $64.0 million. They reaffirmed 2022 revenue guidance for Crysvita between $250 million and $260 million and Dojolvi between $55 million and $65 million. The company completed a $500 million royalty interest sale for Crysvita. Operating expenses reached $230.9 million, leading to a net loss of $158.2 million. The firm continues to develop its extensive pipeline, including late-stage products for various rare diseases.